Immune dysregulation in the functional gastrointestinal disorders

European Journal of Clinical Investigation

Volumn 45, Issue 12, 2015, Pages 1350-1359

  Keely, Simon ^a   Walker, Marjorie M ^b   Marks, Ellen ^a   Talley, Nicholas J ^b  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Dyspepsia; Eosinophils; Functional gastrointestinal disorders; Irritable bowel syndrome; Microbiome; Mucosal immunology

Indexed keywords

ALLERGY; ALTERNATIVE HYPOTHESIS; ATOPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DYSBIOSIS; HOMEOSTASIS; HUMAN; IMMUNE DYSREGULATION; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; DYSPEPSIA; GASTROINTESTINAL DISEASE; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOPATHOLOGY; INTESTINE MUCOSA; IRRITABLE COLON;

DYSBIOSIS; DYSPEPSIA; GASTROINTESTINAL DISEASES; HOMEOSTASIS; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM DISEASES; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; PHENOTYPE;

EID: 84983095630     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12548     Document Type: Review

References (118)

1. Rome F. Guidelines - Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006;15:307-12.
2. Talley NJ. Functional gastrointestinal disorders in 2007 and Rome III: something new, something borrowed, something objective. Rev Gastroenterol Disord 2007;7:97-105.
3. Icks A, Haastert B, Enck P, Rathmann W, Giani G. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol 2002;40:177-83.
4. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol 2002;97:2290-9.
5. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009;41:772-80.
6. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409-15.
7. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67-71.
8. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97-105.
9. Bischoff SC, Gebhardt T. Role of mast cells and eosinophils in neuroimmune interactions regulating mucosal inflammation in inflammatory bowel disease. Adv Exp Med Biol 2006;579:177-208.
10. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011;46:421-31.
11. Walker MM, Salehian SS, Murray CE, Rajendran A, Hoare JM, Negus R et al. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010;31:1229-36.
12. Walker MM, Talley NJ, Prabhakar M, Pennaneac'h CJ, Aro P, Ronkainen J et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009;29:765-73.
13. Walker MM, Warwick A, Ung C, Talley NJ. The role of eosinophils and mast cells in intestinal functional disease. Curr Gastroenterol Rep 2011;13:323-30.
14. Kindt S, Van Oudenhove L, Broekaert D, Kasran A, Ceuppens JL, Bossuyt X et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:389-98.
15. Simren M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159-76.
16. Beaugerie L, Sokol H. [Acute infectious diarrhea in adults: epidemiology and management]. Presse Med 2013;42:52-9.
17. Ford AC, Moayyedi P. Dyspepsia. Curr Opin Gastroenterol 2013;29:662-8.
18. Liebregts T, Adam B, Bredack C, Gururatsakul M, Pilkington KR, Brierley SM et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011;106:1089-98.
19. Kindt S, Tertychnyy A, de Hertogh G, Geboes K, Tack J. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil 2009;21:832-e56.
20. Aro P, Talley NJ, Johansson SE, Agreus L, Ronkainen J. Anxiety is linked to new-onset dyspepsia in the Swedish population: a 10-year follow-up study. Gastroenterology 2015;148:928-37.
21. Langeluddecke PM. Psychological aspects of irritable bowel syndrome. Aust N Z J Psychiatry 1985;19:218-26.
22. Vu J, Kushnir V, Cassell B, Gyawali CP, Sayuk GS. The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders. Neurogastroenterol Motil 2014;26:1323-32.
23. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61:1284-90.
24. Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 2013;62:1456-65.
25. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73.
26. Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic opinions. Scand J Gastroenterol 2013;48:995-1009.
27. Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 2006;19:1638-45.
28. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008;23:1689-94.
29. Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, Shih W et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262-72.
30. Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, Dupont HL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One 2014;9:e93144.
31. Chen J, Zhang Y, Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 2012;12:91.
32. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-101.
33. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
34. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:48-53.
35. Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J 2014;2:505-12.
36. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005;34:235-45, vi-vii.
37. Mearin F, Perello A, Balboa A. [Irritable bowel syndrome and inflammatory bowel disease: is there a connection?]. Gastroenterol Hepatol 2009;32:364-72.
38. Quigley EM, Bernstein CN. "Irritable bowel symptoms" in inflammatory bowel disease: diagnostic uncertainty meets pathological reality. Am J Gastroenterol 2012;107:1483-5.
39. Spiller RC. Overlap between irritable bowel syndrome and inflammatory bowel disease. Dig Dis 2009;27(Suppl 1):48-54.
40. Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013;38:44-51.
41. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474-82.
42. Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GN, van Deventer SJ. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut 1997;40:241-6.
43. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20.
44. Mudter J, Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007;13:1016-23.
45. Al-Haddad S, Riddell RH. The role of eosinophils in inflammatory bowel disease. Gut 2005;54:1674-5.
46. De Cruz P, Prideaux L, Wagner J, Ng SC, McSweeney C, Kirkwood C et al. Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2012;18:372-90.
47. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010;138:1276-85.
48. Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ 3rd. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-12.
49. Oshima T, Toyoshima F, Nakajima S, Fukui H, Watari J, Miwa H. Genetic factors for functional dyspepsia. J Gastroenterol Hepatol 2011;26(Suppl 3):83-7.
50. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005;14:3499-506.
51. Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P, Dong X et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 2008;205:1049-62.
52. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
53. Camilleri M, Carlson P, McKinzie S, Zucchelli M, D'Amato M, Busciglio I et al. Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis. Neurogastroenterol Motil 2011;23:935-e398.
54. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-6.
55. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006;131:445-50; quiz 660.
56. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-13.
57. Berkowitz D, Peri R, Lavy A, Kessel A. Increased Toll-like receptor 9 expression by B cells from inflammatory bowel disease patients. Hum Immunol 2013;74:1519-23.
58. Bereswill S, Kuhl AA, Alutis M, Fischer A, Mohle L, Struck D et al. The impact of Toll-like-receptor-9 on intestinal microbiota composition and extra-intestinal sequelae in experimental Toxoplasma gondii induced ileitis. Gut Pathog 2014;6:19.
59. Schmulson M, Chey WD. Abnormal immune regulation and low-grade inflammation in IBS: does one size fit all? Am J Gastroenterol 2012;107:273-5.
60. Jung Y, Rothenberg ME. Roles and regulation of gastrointestinal eosinophils in immunity and disease. J Immunol 2014;193:999-1005.
61. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 2015;75:14-24.
62. Blanchard C, Rothenberg ME. Chemotactic factors associated with eosinophilic gastrointestinal diseases. Immunol Allergy Clin North Am 2009;29:141-8, xi.
63. Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 2010;40:563-75.
64. Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr 2004;38:343-51.
65. Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol 2009;9:32.
66. Lampinen M, Ronnblom A, Amin K, Kristjansson G, Rorsman F, Sangfelt P et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005;54:1714-20.
67. Woodruff SA, Masterson JC, Fillon S, Robinson ZD, Furuta GT. Role of eosinophils in inflammatory bowel and gastrointestinal diseases. J Pediatr Gastroenterol Nutr 2011;52:650-61.
68. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
69. Philpott H, Gibson P, Thien F. Irritable bowel syndrome - an inflammatory disease involving mast cells. Asia Pac Allergy 2011;1:36-42.
70. Schappi MG, Borrelli O, Knafelz D, Williams S, Smith VV, Milla PJ et al. Mast cell-nerve interactions in children with functional dyspepsia. J Pediatr Gastroenterol Nutr 2008;47:472-80.
71. Brandtzaeg P. Food allergy: separating the science from the mythology. Nat Rev Gastroenterol Hepatol 2010;7:380-400.
72. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013;108:1066-74.
73. Chafen JJ, Newberry SJ, Riedl MA, Bravata DM, Maglione M, Suttorp MJ et al. Diagnosing and managing common food allergies: a systematic review. JAMA 2010;303:1848-56.
74. Lam M, Hull L, Imrie A, Snidvongs K, Chin D, Pratt E et al. Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis. Am J Rhinol Allergy 2015;29:175-81.
75. Yazar A, Atis S, Konca K, Pata C, Akbay E, Calikoglu M et al. Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome. Am J Gastroenterol 2001;96:1511-6.
76. Jones MP, Walker MM, Ford AC, Talley NJ. The overlap of atopy and functional gastrointestinal disorders among 23, 471 patients in primary care. Aliment Pharmacol Ther 2014;40:382-91.
77. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108:516-20.
78. Sjogren YM, Jenmalm MC, Bottcher MF, Bjorksten B, Sverremark-Ekstrom E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy 2009;39:518-26.
79. Turnbaugh PJ, Quince C, Faith JJ, McHardy AC, Yatsunenko T, Niazi F et al. Organismal, genetic and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. Proc Natl Acad Sci USA 2010;107:7503-8.
80. Martinez I, Muller CE, Walter J. Long-term temporal analysis of the human fecal microbiota revealed a stable core of dominant bacterial species. PLoS One 2013;8:e69621.
81. Srikanth CV, McCormick BA. Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk. Interdiscip Perspect Infect Dis 2008;2008:626827.
82. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaption of mammals to their commensal intestinal microbiota. Semin Immunol 2007;19:59-69.
83. Yamamoto M, Yamaguchi K, Munakata K, Takashima K, Nishiyama M, Hioki K et al. A microarray analysis of gnotobiotic mice indicating that microbial exposure during the neonatal period plays an essential role in immune system development. BMC Genomics 2012;13:335.
84. Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999;29:342-6.
85. Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol 2010;10:23.
86. Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010;16:2978-90.
87. Collins CB, McGrath J, Baird AW, Campion DP. Effect of mast cell degranulation on chicken ileal ion transport in vitro. Poult Sci 2007;86:843-9.
88. Keely S, Feighery L, Campion DP, O'Brien L, Brayden DJ, Baird AW. Chloride-led disruption of the intestinal mucous layer impedes Salmonella invasion: evidence for an 'enteric tear' mechanism. Cell Physiol Biochem 2011;28:743-52.
89. Keely S, Kelly CJ, Weissmueller T, Burgess A, Wagner BD, Robertson CE et al. Activated fluid transport regulates bacterial-epithelial interactions and significantly shifts the murine colonic microbiome. Gut Microbes 2012;3:250-60.
90. Sun Y, Zhang M, Chen CC, Gillilland M 3rd, Sun X, El-Zaatari M et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013;144:1478-87, 1487.e1-8.
91. Wlodarska M, Thaiss CA, Nowarski R, Henao-Mejia J, Zhang JP, Brown EM et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 2014;156:1045-59.
92. Gagliani N, Palm NW, de Zoete MR, Flavell RA. Inflammasomes and intestinal homeostasis: regulating and connecting infection, inflammation and the microbiota. Int Immunol 2014;26:495-9.
93. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85.
94. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil 2015;27:19-29.
95. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther 2012;35:403-13.
96. Urita Y, Goto M, Watanabe T, Matsuzaki M, Gomi A, Kano M et al. Continuous consumption of fermented milk containing Bifidobacterium bifidum YIT 10347 improves gastrointestinal and psychological symptoms in patients with functional gastrointestinal disorders. Biosci Microbiota Food Health 2015;34:37-44.
97. Russell SL, Gold DR, Willing BP, Thorson L, McNagny KM, Finlay BB. Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma. Gut Microbes 2013;4:158-64.
98. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012;13:440-7.
99. Wang JY, Liu LF, Chen CY, Huang YW, Hsiung CA, Tsai HJ. Acetaminophen and/or antibiotic use in early life and the development of childhood allergic diseases. Int J Epidemiol 2013;42:1087-99.
100. Zhang L-L, Chen X, Zheng P-Y, Luo Y, Lu G-F, Liu Z-Q et al. Oral Bifidobacterium modulates intestinal immune inflammation in mice with food allergy. J Gastroenterol Hepatol 2010;25:928-34.
101. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013;341:569-73.
102. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK et al. Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci USA 2014;111:13145-50.
103. Keely S, Foster PS. Stop press: eosinophils drafted to join the Th17 team. Immunity 2015;43:7-9.
104. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011;12:568-75.
105. Griseri T, Arnold IC, Pearson C, Krausgruber T, Schiering C, McKenzie B et al. GM-CSF-activated eosinophils as mediators of IL-23 driven chronic colitis. Immunity 2015;43:187-99.
106. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013;13:145-9.
107. Hepworth MR, Monticelli LA, Fung TC, Ziegler CG, Grunberg S, Sinha R et al. Innate lymphoid cells regulate CD4 + T-cell responses to intestinal commensal bacteria. Nature 2013;498:113-7.
108. Roediger B, Weninger W. Group 2 innate lymphoid cells in the regulation of immune responses. Adv Immunol 2015;125:111-54.
109. Lefrancais E, Duval A, Mirey E, Roga S, Espinosa E, Cayrol C et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci USA 2014;111:15502-7.
110. Nussbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molofsky AB et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 2013;502:245-8.
111. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J et al. Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 2015;43:161-74.
112. Spencer SP, Wilhelm C, Yang Q, Hall JA, Bouladoux N, Boyd A et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science 2014;343:432-7.
113. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol 2014;222:R113-27.
114. Jin C, Flavell RA. Innate sensors of pathogen and stress: linking inflammation to obesity. J Allergy Clin Immunol 2013;132:287-94.
115. Lee CG, Lee JK, Kang YS, Shin S, Kim JH, Lim YJ et al. Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome. Am J Gastroenterol 2015;110:310-9.
116. Pickett-Blakely O. Obesity and irritable bowel syndrome: a comprehensive review. Gastroenterol Hepatol (N Y) 2014;10:411-6.
117. Bouchoucha M, Fysekidis M, Julia C, Airinei G, Catheline JM, Cohen R et al. Body mass index association with functional gastrointestinal disorders: differences between genders. Results from a study in a tertiary center. J Gastroenterol 2015. [Epub ahead of print].
118. Le Pluart D, Sabate JM, Bouchoucha M, Hercberg S, Benamouzig R, Julia C. Functional gastrointestinal disorders in 35, 447 adults and their association with body mass index. Aliment Pharmacol Ther 2015;41:758-67.